These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22287276)

  • 1. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
    Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
    Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
    Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
    Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
    Dalrymple SL; Becker RE; Isaacs JT
    Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
    Olsson A; Björk A; Vallon-Christersson J; Isaacs JT; Leanderson T
    Mol Cancer; 2010 May; 9():107. PubMed ID: 20470445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tasquinimod: a novel drug in advanced prostate cancer.
    Osanto S; van Poppel H; Burggraaf J
    Future Oncol; 2013 Sep; 9(9):1271-81. PubMed ID: 23980674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
    Schweizer MT; Carducci MA
    Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
    Isaacs JT; Pili R; Qian DZ; Dalrymple SL; Garrison JB; Kyprianou N; Björk A; Olsson A; Leanderson T
    Prostate; 2006 Dec; 66(16):1768-78. PubMed ID: 16955399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
    Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
    J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.
    Wang Q; Tiffen J; Bailey CG; Lehman ML; Ritchie W; Fazli L; Metierre C; Feng YJ; Li E; Gleave M; Buchanan G; Nelson CC; Rasko JE; Holst J
    J Natl Cancer Inst; 2013 Oct; 105(19):1463-73. PubMed ID: 24052624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
    Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
    Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
    Melnyk O; Zimmerman M; Kim KJ; Shuman M
    J Urol; 1999 Mar; 161(3):960-3. PubMed ID: 10022734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
    Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
    Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
    Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
    Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
    Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS
    J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of tasquinimod in the treatment of advanced prostate cancer.
    Williamson SC; Hartley AE; Heer R
    Drug Des Devel Ther; 2013; 7():167-74. PubMed ID: 23662046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling.
    Man K; Ng KT; Xu A; Cheng Q; Lo CM; Xiao JW; Sun BS; Lim ZX; Cheung JS; Wu EX; Sun CK; Poon RT; Fan ST
    Clin Cancer Res; 2010 Feb; 16(3):967-77. PubMed ID: 20103676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
    Kim SJ; Johnson M; Koterba K; Herynk MH; Uehara H; Gallick GE
    Clin Cancer Res; 2003 Nov; 9(14):5161-70. PubMed ID: 14613995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.